

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/006966 A1

(51) International Patent Classification⁷: A61K 51/12.
47/48, 49/00, A61P 35/00

[GR/GR]: University of Crete, School of Medicine, P.O.
Box 2208, GR-710 03 Heraklion (GR).

(21) International Application Number:
PCT/IB2003/002785

(74) Agents: CARLSSON, Eva et al.: International Patent
Bureau A/S, Høje Taastrup Boulevard 23. DK-2630 Taa-
strup (DK).

(22) International Filing Date: 14 July 2003 (14.07.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT (util-
ity model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), DE (util-
ity model), DK (utility model), DK, DM, DZ, EC, EE
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20020100335 16 July 2002 (16.07.2002) GR

(71) Applicant (*for all designated States except US*):
MEDEXIS S.A. [GR/GR]; 4 Asklepiou Street, GR-145 68
Kryoneri (GR).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): CASTANAS, Elias

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: STEROID CONJUGATES. PREPARATION THEREOF AND THE USE THEREOF

(57) Abstract: Conjugates comprising one
or more steroids conjugated with one or
more mammalian proteins are disclosed.
The conjugates are useful for diagnosis or
treatment of solid cancer and haematological
malignancies. Further the conjugates exhibits
a synergistic action together with a cytoskeleton
acting drug such as Taxol[®], which enable the
treatment of cancers that otherwise would be
non responsive to Taxol[®].

